OrbiMed Advisors Increases Stake in ImageneBio, Inc. via 2026 PIPE Warrants

On April 29, 2026, OrbiMed Advisors LLC and its affiliates filed Amendment No. 6 to their Schedule 13D for ImageneBio, Inc. (formerly Ikena Oncology, Inc.), reporting an increased beneficial ownership position. The Reporting Persons acquired an aggregate of 721,292 pre-funded warrants through a private placement (2026 PIPE) that closed on April 14, 2026. Specifically, OrbiMed Private Investments VI, LP purchased 336,603 warrants and OrbiMed Genesis Master Fund, L.P. purchased 384,689 warrants at a price of $5.199 per warrant. Following these transactions, the Reporting Persons collectively beneficially own 1,495,045 shares, representing approximately 13.1% of the issuer's outstanding common stock. This total includes 1,089,665 shares held by OPI VI, 405,380 shares by Genesis, and 135,516 shares by Worldwide Healthcare Trust PLC. The pre-funded warrants are presently exercisable, subject to a 19.99% beneficial ownership blocker. OrbiMed Advisors exercises voting and investment power over these securities through a management committee. The filing also notes that David P. Bonita, a member of OrbiMed Advisors, serves on the issuer's Board of Directors.